Eidson v. Medtronic, Inc.
981 F. Supp. 2d 868
N.D. Cal.2013Background
- Plaintiffs Scott and April Bell and Plaintiff Richard Eidson underwent spinal surgeries using Medtronic Infuse Device components.
- Infuse Device is a three-component system: LT Cage, rhBMP-2 bone graft, and a carrier scaffold; labeling required LT Cage with the graft.
- Device is Class III with FDA PMA; off-label uses include posterior approaches without LT Cage, among others.
- Defendants allegedly promoted off-label use and failed to report adverse events; fraud, misrepresentation, and various product liability claims were pleaded.
- Court grants partial preemption-based dismissal: express preemption of certain claims; Buckman implied preemption discussed; design defect claims barred by California law; statute-of-limitations issues apply to Bells.
- Judicial notice granted for FDA PMA documents; case related to another Bell case; procedural posture: motions to dismiss under Rule 12(b)(6) with leave to amend where appropriate.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Eidson’s fraud claims are preempted by the MDA | Eidson argues some fraud claims align with state tort law and may survive preemption. | Defendants contend certain fraud theories (warnings) are express preemption; some off-label promotion theories may parallel federal law. | Fraud claims based on off-label promotion survive preemption; those based on FDA-approved warnings are express preempted. |
| Whether Eidson’s failure-to-warn claim based on off-label promotion is preempted | Eidson asserts state-law duties parallel FDCA prohibitions on off-label promotion. | Such claims might be preempted as arising from federal regulation. | Not expressly preempted; not precluded; dismissed for lack of causal nexus and allowed leave to amend. |
| Whether Eidson’s failure-to-warn claim based on reporting adverse events to the FDA is preempted | Claim premised on duty to report adverse events to FDA. | This is potentially Buckman-type implied preemption if it relies solely on FDCA. | Not preempted; dismissed without prejudice for failure to show causal link. |
| Whether Eidson’s negligence claim based on off-label promotion is preempted | Promoting off-label use involves state duties parallel to federal law. | Such claim is impliedly preempted as it exists solely to enforce FDA ban on off-label promotion. | Impliedly preempted for the off-label-promotion theory; other theories not preempted with leave to amend. |
| Whether Eidson’s design-defect claim is cognizable under California law | Design defect liability should be evaluated under California law. | California law bars strict liability design defect claims for prescriptions devices. | Design-defect claim dismissed with prejudice. |
| Whether Bells’ claims are time-barred by statute of limitations | Discovery rule may toll accrual due to concealment. | Two-year California product-defect SOL governs; discovery rule inadequately pled. | Bell claims dismissed with leave to amend for Bells to plead discovery facts. |
Key Cases Cited
- Riegel v. Medtronic, Inc., 552 U.S. 312 (U.S. 2008) (express preemption framework for PMA devices; requirements vs. parallel claims)
- Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341 (U.S. 2001) (implied preemption: government-driven FDCA actions; claims must rely on traditional state law)
- Stengel v. Medtronic, Inc., 704 F.3d 1224 (9th Cir. 2013) (Buckman-style implied preemption analysis in Infuse Device cases; parallel duties concept)
- Caplinger v. Medtronic, Inc., 921 F.Supp.2d 1206 (W.D. Okla. 2013) (fraud-based claims based on warnings preempted; off-label promotion addressed as parallel)
- Houston v. Medtronic,, Inc., 957 F. Supp. 2d 1166 (C.D. Cal. 2013) (off-label promotion findings not preempted; parallel claims analysis applied)